G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates

Antiviral Research

Volumn 91, Issue 2, 2011, Pages 187-194

  Wang, Yang ^a   Rowley, Kirk J ^a   Booth, Brian J ^a   Sloan, Susan E ^a   Ambrosino, Donna M ^a   Babcock, Gregory J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

G glycoprotein; Monoclonal antibody; Neutralization; Pseudovirus; Rabies virus

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RAB1; MUTANT PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ARTICLE; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RABIES VIRUS; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ASPARAGINE; BINDING SITES, ANTIBODY; CLONING, MOLECULAR; GLYCOPROTEINS; HEK293 CELLS; HUMANS; MUTAGENESIS, SITE-DIRECTED; NEUTRALIZATION TESTS; POINT MUTATION; RABIES VIRUS; SEQUENCE ANALYSIS, PROTEIN; TRANSFECTION; VIRAL ENVELOPE PROTEINS;

LENTIVIRUS; RABIES VIRUS;

EID: 79959698307     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.06.002     Document Type: Article

References (31)

1. Babcock G.J., Esshaki D.J., Thomas W.D., Ambrosino D.M. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J. Virol. 2004, 78:4552-4560.
2. Babcock G., Leav B., Sloan S., Singh S., Fehlner-Gardiner C., Wandeler A., Kapre S., Molrine D., Ambrosino D. Fully human monoclonal antibody 17C7 neutralizes rabies virus endemic to Asia, 19th International Conference on Rabies in the Americas 2008, Atlanta, GA.
3. Bakker A.B.H., Marissen W.E., Kramer R.A., Rice A.B., Weldon W.C., Niezgoda M., Hanlon C.A., Thijsse S., Backus H.H.J., de Kruif J., Dietzschold B., Rupprecht C.E., Goudsmit J. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol. 2005, 79:9062-9068.
4. Benmansour A., Leblois H., Coulon P., Tuffereau C., Gaudin Y., Flamand A., Lafay F. Antigenicity of rabies virus glycoprotein. J. Virol. 1991, 65:4198-4203.
5. Bunschoten H., Gore M., Claassen I.J., Uytdehaag F.G., Dietzschold B., Wunner W.H., Osterhaus A.D. Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. J. Gen. Virol. 1989, 70(Pt 2):291-298.
6. Coulon P., Rollin P., Aubert M., Flamand A. Molecular basis of rabies virus virulence. I. Selection of avirulent mutants of the CVS strain with anti-G monoclonal antibodies. J. Gen. Virol. 1982, 61:97-100.
7. Coulon P., Ternaux J.P., Flamand A., Tuffereau C. An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro. J. Virol. 1998, 72:273-278.
8. Dietzschold B., Wunner W.H., Wiktor T.J., Lopes A.D., Lafon M., Smith C.L., Koprowski H. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc. Natl. Acad. Sci. USA 1983, 80:70-74.
9. Dietzschold B., Tollis M., Lafon M., Wunner W.H., Koprowski H. Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies. Virology 1987, 161:29-36.
10. Dietzschold B., Gore M., Marchadier D., Niu H.S., Bunschoten H.M., Otvos L., Wunner W.H., Ertl H.C., Osterhaus A.D., Koprowski H. Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J. Virol. 1990, 64:3804-3809.
11. Enssle K., Kurrle R., Kohler R., Muller H., Kanzy E.J., Hilfenhaus J., Seiler F.R. A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 1991, 10:547-556.
12. Flamand A., Wiktor T.J., Koprowski H. Use of hybridoma monoclonal antibodies in the detection of antigenic differences between rabies and rabies-related virus proteins. II. The glycoprotein. J. Gen. Virol. 1980, 48:105-109.
13. Hanlon C.A., DeMattos C.A., DeMattos C.C., Niezgoda M., Hooper D.C., Koprowski H., Notkins A., Rupprecht C.E. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 2001, 19:3834-3842.
14. Hemachudha T., Mitrabhakdi E., Wilde H., Vejabhuti A., Siripataravanit S., Kingnate D. Additional reports of failure to respond to treatment after rabies exposure in Thailand. Clin. Infect. Dis. 1999, 28:143-144.
15. Knobel D.L., Cleaveland S., Coleman P.G., Fevre E.M., Meltzer M.I., Miranda M.E., Shaw A., Zinsstag J., Meslin F.X. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ. 2005, 83:360-368. (Epub 2005 Jun 2024).
16. Lafon M., Wiktor T.J., Macfarlan R.I. Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. J. Gen. Virol. 1983, 64(Pt 4):843-851.
17. Lafon M., Ideler J., Wunner W.H. Investigation of the antigenic structure of rabies virus glycoprotein by monoclonal antibodies. Dev. Biol. Stand. 1984, 57:219-225.
18. Leav B., Kulkarni P., Gogtay N., Cheslock P., Martin V., Wiggin H., Ambrosino D., Molrine D., Kapre S. A Human Monoclonal Antibody to Rabies Virus Provides Protective Neutralizing Activity: Results of a Phase 1 Study, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2010, Boston, MA.
19. Marissen W.E., Kramer R.A., Rice A., Weldon W.C., Niezgoda M., Faber M., Slootstra J.W., Meloen R.H., Clijsters-van der Horst M., Visser T.J., Jongeneelen M., Thijsse S., Throsby M., de Kruif J., Rupprecht C.E., Dietzschold B., Goudsmit J., Bakker A.B. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J. Virol. 2005, 79:4672-4678.
20. Montano-Hirose J.A., Lafage M., Weber P., Badrane H., Tordo N., Lafon M. Protective activity of a murine monoclonal antibody against European bat lyssavirus 1 (EBL1) infection in mice. Vaccine 1993, 11:1259-1266.
21. Ni Y., Tominaga Y., Honda Y., Morimoto K., Sakamoto S., Kawai A. Mapping and characterization of a sequential epitope on the rabies virus glycoprotein which is recognized by a neutralizing monoclonal antibody, RG719. Microbiol. Immunol. 1995, 39:693-702.
22. Prehaud C., Coulon P., LaFay F., Thiers C., Flamand A. Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J. Virol. 1988, 62:1-7.
23. Prosniak M., Faber M., Hanlon C.A., Rupprecht C.E., Hooper D.C., Dietzschold B. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J. Infect. Dis. 2003, 188:53-56.
24. Schumacher C.L., Dietzschold B., Ertl H.C., Niu H.S., Rupprecht C.E., Koprowski H. Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. J. Clin. Invest. 1989, 84:971-975.
25. Seif I., Coulon P., Rollin P.E., Flamand A. Rabies virulence. effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein. J. Virol. 1985, 53:926-934.
26. Sloan S.E., Hanlon C., Weldon W., Niezgoda M., Blanton J., Self J., Rowley K.J., Mandell R.B., Babcock G.J., Thomas W.D., Rupprecht C.E., Ambrosino D.M. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 2007, 25:2800-2810. Epub 2006 Dec 2829.
27. Consultation on a Rabies Monoclonal Antibody Cocktail for Rabies Post Exposure Treatment 2002, WHO, WHO, Geneva.
28. WHO, 2005. World Health Organization - Rabies Fact Sheet 99, revised September 2005.
29. Wiktor T.J., Koprowski H. Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. Proc. Natl. Acad. Sci. USA 1978, 75:3938-3942.
30. Wilde H., Choomkasien P., Hemachudha T., Supich C., Chutivongse S. Failure of rabies postexposure treatment in Thailand. Vaccine 1989, 7:49-52.
31. Wilde H., Sirikawin S., Sabcharoen A., Kingnate D., Tantawichien T., Harischandra P.A., Chaiyabutr N., de Silva D.G., Fernando L., Liyanage J.B., Sitprija V. Failure of postexposure treatment of rabies in children. Clin. Infect. Dis. 1996, 22:228-232.